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Abstract
Bacterial vaginosis (BV) is a common vaginal disorder in women of reproductive age. Since the initial work of Leopoldo
in 1953 and Gardner and Dukes in 1955, researchers have not been able to identify the causative etiologic agent of BV.
There is increasing evidence, however, that BV occurs when Lactobacillus spp., the predominant species in healthy
vaginal flora, are replaced by anaerobic bacteria, such as Gardenella vaginalis, Mobiluncus curtisii, M. mulieris, other
anaerobic bacteria and/or Mycoplasma hominis. Worldwide, it estimated that 20–30 % of women of reproductive
age attending sexually transmitted infection (STI) clinics suffer from BV, and that its prevalence can be as high as
50–60 % in high-risk populations (e.g., those who practice commercial sex work (CSW). Epidemiological data
show that women are more likely to report BV if they: 1) have had a higher number of lifetime sexual partners;
2) are unmarried; 3) have engaged in their first intercourse at a younger age; 4) have engaged in CSW, and 5)
practice regular douching. In the past decade, several studies have provided evidence on the contribution of
sexual activity to BV. However, it is difficult to state that BV is a STI without being able to identify the
etiologic agent. BV has also emerged as a public health problem due to its association with other STIs,
including: human immunodeficiency virus (HIV), herpes simplex virus type 2 (HSV-2), Chlamydia trachomatis
(CT) and Neisseria gonorrhoeae (NG). The most recent evidence on the association between BV and CT/NG
infection comes from two secondary analyses of cohort data conducted among women attending STI clinics.
Based on these studies, women with BV had a 1.8 and 1.9-fold increased risk for NG and CT infection, respectively.
Taken together, BV is likely a risk factor or at least an important contributor to subsequent NG or CT infection in
high-risk women. Additional research is required to determine whether this association is also present in other
low-risk sexually active populations, such as among women in the US military. It is essential to conduct large
scale cross-sectional or population-based case-control studies to investigate the role of BV as a risk factor for
CT/NG infections. These studies could lead to the development of interventions aimed at reducing the burden
associated with bacterial STIs worldwide.
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Over the past two decades, several in vitro and in vivo
studies have reported that bacterial vaginosis (BV), a com-
mon vaginal condition in women of reproductive age, is a
biological risk factor associated with transmission of sexu-
ally transmitted infections (STIs), including chlamydia and
gonorrhea infection. Although the aetiology of bacterial
vaginosis is still unknown, it is believed that occurs when
Lactobacillus spp., the predominant species in healthy
vaginal flora, is replaced by anaerobes, mainly Gardnerella
vaginalis. The purpose of this review is to provide informa-
tion that clearly discusses on etiology and epidemiology of
BV, and especially its association with transmission of
chlamydia and gonorrhea infections. For STI control
efforts, the role of BV on these common bacterial infections
is an important area for research because there is evidence
from randomized trials that screening and treating of
asymptomatic women with BV reduce the risk of infection.
Bacterial vaginosis
Etiology
In 1892, Doderlein identified, by culturing vaginal secre-
tions of healthy women, Lactobacillus spp., a gram-positive
facultative anaerobic bacteria first discovered in sour milk
by Scheele in 1780 and subsequently in humans by
Folwarczny in 1858 [1]. In 1921, Schroeder confirmed
Doderlein’s findings and developed three grades to assess
the microbial composition of the vaginal flora. These
grades are as follows: 1) healthy vaginal microflora
(grade I); 2) Lactobacillus spp. partially replaced by
other bacteria (grade II), and 3) Lactobacillus spp.
completely replaced by other bacteria (grade III) [2].
Seven years after Schroeder’s work, Thomas identified
Doderlein’s bacteria by microscopy and culture as
Lactobacillus acidophilus [3]. Based on these findings,
Thomas and Schroeder suggested that vaginal discharge is
associated with a lactobacilli-deficiency.
Until the mid-1950s, physicians used the term “non-
specific vaginitis” for women with lactobacillary grade III
vaginal discharge without yeast cells or Trichomonas
vaginalis [1]. In 1953, Leopold, a US Army captain, was
the first to isolate and describe a small, gram-negative,
nonmotile, nonencapsuled, rod-shaped bacterium from
cervical swabs of women with cervicitis and from men
with prostatitis. Although he did not name its species,
he suggested that the organism was a member of the
genus Haemophilus [4]. Two years later, Gardner and
Dukes isolated the organism reported by Leopold in
women with non-specific bacterial vaginitis, and based
on its origin, the organism was named Haemophilus
vaginalis. They were also the first to describe H. vagina-
lis as the causative agent of non-specific vaginal infec-
tions [5]. In 1978, Pheifer confirmed the findings of
Leopold, Gardner and Dukes after treating women withnon-specific vaginitis with metronidazole, an antimicro-
bial drug used to treat bacterial infections [6]. Since the
first report of Gardner and Dukes in 1955, numerous
researchers have identified H. vaginalis in women
attending venereal disease clinics in the US [7, 8].
Questions have been raised about the identification of
H. vaginalis as the etiologic agent of non-specific vagin-
itis since the initial publication by Gardner and Dukes
[9]. In the first study by Gardner and Dukes, 2 out of 13
healthy women became infected after being inoculated
with a pure culture of H. vaginalis. In their second
study, 7 out of 29 women inoculated with H. vaginalis
became infected. In their third study conducted with 15
healthy women who were inoculated intravaginally with
H. vaginalis, 11 developed the infection. Combined,
these experiments showed approximately 35 % of inocu-
lated women became infected with H. vaginalis. For
Gardner and Dukes, the isolation of H. vaginalis in
women inoculated with the bacteria was sufficient proof
to postulate that H. vaginalis was the etiologic agent of
non-specific vaginitis [10]. Nevertheless, most researchers
rejected this finding of causality because it did not meet
Koch’s postulates, proposed in 1890, on the cause-and-
effect relationship between bacteria and disease [11].
In the 1960s, there was considerable criticism on
whether this small anaerobic bacterium belonged to the
genus Haemophilus. In 1963, Zinnemann and Turner
proposed renaming H. vaginalis as Corynebacterim vagi-
nale because it has a corynebacterium-like morphology
[12]. In 1979, Greenwood and Pickett indicated that H.
vaginalis had no established genus, and thus, a new
genus should be established for this bacterium [13].
Using several biochemical methods, such as DNA-DNA
hybridization, biochemical analysis of the cell wall, and
electron microscopy, in 1980, Greenwood and Pickett
showed that H. vaginalis did not belong to the genus
Haemophilus and renamed it Gardnerella vaginalis in
honor of Gardner who had first reported the association
between non-specific vaginitis and this bacteria [14]. In
the same year, the name G. vaginalis was also supported
by a second taxonomic study conducted by Piot [15].
Since 1983 physicians have used the term “bacterial vagin-
osis” to differentiate the vaginal discharge syndrome
described by Gardner and Dukes from those caused by
other microorganisms (e.g., parasites or fungi).
Other microorganisms in the vaginal microflora besides
G. vaginalis have been discovered in the past two decades.
These include Mobiluncus curtisii, M. mulieris, Myco-
plasma hominis and anaerobic bacteria, such as Bac-
teroides spp., Prevotela spp., Peptostreptococcus spp.,
Fusobacterium spp., and Porphyromonas spp [1]. G.
vaginalis has also been detected in culture samples
from nearly all symptomatic women with bacterial
vaginosis (BV) and in approximately 50 % of the
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why other species of the genus Lactobacillus (e.g., L.
gasseri, L. jensenii, L. iners, and L. crispatus), that also
produce hydrogen peroxide (an antimicrobial product
protecting against deleterious microorganisms), lactic
acid (which maintains the normal vaginal pH balance
between 3.5 and 4.5), and bacteriocins (homegrown
antibiotics that inhibit the growth of harmful organ-
isms within the vagina) are superseded by other path-
ogens (e.g., G. vaginalis) are unknown, as is their
overall role in the vaginal microflora [17]. According
to a conceptual model for BV pathogenesis developed
by Schwebke in 2014, G. vaginalis is the pathogen re-
sponsible for the initiation of BV, with other patho-
gens acting as secondary “intruders” [18]. It is
estimated that Lactobacillus spp. comprise 90–95 %
of the total bacteria count in the healthy vaginal flora
of reproductive age women and maintain balance in
the vaginal ecosystem [19].
Prevalence
For clinicians, BV is a common vaginal condition
characterized by at least three of the following four
Amsel criteria: 1) thin, gray/white discharge; 2) malodor-
ous “fishy” discharge upon adding 10 % potassium hydrox-
ide; 3) high vaginal pH (>4.5), and 4) identification of
vaginal epithelial cells heavily coated with bacteria (i.e.,
“clue cells”) [20]). For research purposes, BV is commonly
diagnosed by a Gram’s stain-based evaluation of vaginal
bacterial morphotypes using the Nugent score (≥7 indi-
cates BV) [21]. It is assumed that BV is characterized by
the replacement of normal vaginal lactobacilli with that of
anaerobic microorganisms (e.g., G. vaginalis, Prevotella,
Peptostreptococcus, and Bacteriodes spp). This replace-
ment causes an imbalance in the vaginal microflora, which
is the pathophysiologic process responsible for the
discharge. It is estimated that 20–30 % of women with
vaginal discharge have BV, although the prevalence can be
as high as 50–60 % in some high-risk sexual behavior
populations [16, 22].
A 2013 systematic review reported that BV prevalence
varies between and within countries worldwide [23].
Women from South and East Africa have higher rates of
BV (68 % in Mozambique, 51 % in Lesotho, 44 % in
Kenya, 37 % in Gambia) compared to women from West
Africa (7 % in Burkina Faso) [21]. In Norway (24 %),
Turkey (23 %), and Poland (19 %), women have moder-
ately high BV rates. Women from Southeast Asia,
Australia, New Zealand, and Indonesia have rates of BV
that are typically greater than 30 %. Women in Latin
America and the Caribbean have lower rates of BV,
except in rural and antenatal populations in Jamaica and
Peru (rates of −40 %). In the US, BV is a common condi-
tion among women, with prevalence varying by race/ethnicity: African-American (51 %), Hispanic (32 %), and
whites (23 %). Similarly, in Canada, aboriginal and indi-
genous women have high BV rates (33 %). Among
female military recruits to the US Marine Corps between
1999 and 2000, the prevalence of BV was 27 % [24].
According to this study, Native American (34 %),
African-American (32 %), and Hispanic (30 %) female
recruits had the highest BV burden. Data from the US
Defense Medical Surveillance System indicates that
between 2004 and 2013, 149,666 (15,000 cases per year)
BV cases were reported in women in the US military. Of
these, 45 % occurred among U.S. Army personnel (un-
published data).
A recent ecological study conducted by Kenyon and
Colebunders among males in 11 countries (Central African
Republic, Brazil, Cote d’Ivoire, Kenya, Lesotho, Philippines,
Singapore, Sri Lanka, Thailand, Zambia, and Tanzania) re-
ported a moderate correlation between the number of
partners (as measured by the question, “Do you now have
one or more than one spouse/regular partner?”) and BV
prevalence (R2 = 0.57) [25]. Recent studies conducted
among pregnant, HIV-positive and infertile women have
also reported high BV prevalences. Among pregnant
women in northeastern Nigeria and Ethiopia, the preva-
lence of BV was 17 and 19 %, respectively [26, 27]; among
human immunodeficiency virus (HIV) positive women, a
BV prevalence of 48 % has been described in India [28],
whereas among infertile women in Qom and Iran the
prevalence of BV was found to be 70 % [29]. Information
on the burden of BV in Eastern Europe is limited. How-
ever, in Bulgaria, by polymerase chain reaction (PCR) and
Gram’s staining methods, the BV prevalence was found to
be 56 and 57 %, respectively [30]. It has also been reported
that the prevalence of BV is high among women with tubal
factor infertility in Nigeria [31].
In recent years, BV among women who have sex with
women (WSW) has received additional research atten-
tion. Between 1995 and 2014, five studies have reported
high prevalence estimates (~25 to ~50 %) among WSW
[32]. Although there is no specific anatomic or physio-
logic reason to explain this high prevalence, it has been
hypothesized that vaginal fluid exchange may represent
an efficient mode of transmission, much as occurs with
penile-vaginal sex. Researchers believe that WSW are
also a unique high-risk population for the study of BV
pathogenesis. Moreover, there is evidence that sexual rela-
tionships and behaviors have a strong influence on BV
acquisition. These findings would support the hypothesis
that BV is sexually transmitted.
Epidemiology and risk factors
Several studies have identified numerous sexual risk be-
haviors and other risk factors associated with BV [32–48].
Women are more likely to suffer from BV if they: 1) report
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unmarried; 3) were at younger at their first inter-
course; 4) self-identify as commercial sex workers
(CSWs), and 5) practice regular douching. Other epi-
demiologic risk factors which have been implicated to
a lesser degree include: 1) a high frequency of vaginal
intercourse (“state frequency”); 2) a history of preg-
nancy, and 3) cigarette smoking [35]. In 2014, Jespers
et al., reported that recent unprotected sex within 14
to 72 h prior to sampling was a risk factor for BV
among CSWs in Kenya, Rwanda, and South Africa;
unprotected sex was measured by the presence of
prostate-specific antigen in the vaginal fluid [37]. This
finding added to the literature the finding that in
high-risk populations, male semen and vaginal pene-
tration influence the development of BV. A recent
systematic review and meta-analysis identified female
genital mutilation or cutting as a risk factor for BV
development [38]. In addition, a secondary data analysis
of HIV-negative CSWs from South Africa, Uganda, Benin,
and India showed that recent vaginal cleansing increases
the risk of BV recurrence and that consistent condom use
decreases the risk of BV [39]. To date, there is no clear
evidence that BV is associated with pelvic inflammatory
disease, although several studies have reported a link
between BV and cervicitis [40].
A recent large cross-sectional study conducted among
53,652 rural married women in China reported that over
35 days of the menstrual cycle, less than 3 days of men-
struation, dysmenorrhea, and usage of an intrauterine
device were associated with BV [41]. Other studies have
also reported that personal hygiene behaviors, such as va-
ginal douching, are consistently associated with BV [42].
On the other hand, current use of hormonal contracep-
tion, the luteal phase of menstrual cycle, a higher income,
and vaginal candidiasis have been reported as protective
factors for BV among women attending cervical screen-
ings in south eastern Brazil [43]. Findings from a large
cohort study conducted among CSWs in Uganda indi-
cated that hormonal contraception was a protective factor
against BV [44]. This finding has been corroborated in a
recent systematic review and meta-analysis, where the au-
thors found that hormonal contraception reduces the risk
of BV, and thus has a potential implication for prevention
[45]. In addition to hormonal contraception, consistent
condom use with a primary partner has been found to
prevent the recurrence BV among CSWs, highlighting the
importance of this barrier method [46]. Although several
studies have found numerous protective and risk factors
associated with BV in different risk behavior groups, data
on the emotional, sexual and social impact of living with
BV is sparse in the literature. A recent study conducted by
Bilardi et al. [47] reported that women with recurrent BV
felt embarrassed, ‘dirty’, ashamed and worried that othersmay detect their malodor and abnormal discharge. There-
fore, BV affected their self-esteem and sex lives by making
them avoid having sexual contact with their partners.
There is additional evidence that oral and anal sex
may increase the risk of BV. Among adolescent girls
who visited sexually transmitted infection (STI) clinics
in Baltimore, Maryland, between 1990 and 2002, BV was
reported more often among those who reported oral and
anal sex [48]. In another study, receptive anal sex before
vaginal sex was independently associated with BV among
773 young sexually active women 18–30 years of age
[49]. In high-risk groups such as WSW, it was found
that the use of vaginal sex toys, oral-anal sex (e.g., anilin-
gus), presence of a BV condition in the female partner
and a higher lifetime number of female sex partners in-
creased the risk of BV [50]. A recent study conducted in
355 lesbian and bisexual women using a computer-
assisted self-interview approach revealed that presence
of Lactobacillus gasseri and vaginal lubricant use in-
creased the risk for BV [51]. In a second study among
196 African American WSW, douching within the past
30 days, younger age (18 years or less) at first sexual en-
counter with a female partner, and two or more male life-
time sexual partners were positively associated with BV
[52]. Data from a 24-month WSW cohort study involving
visits every 3 months found that receptive oral sex, BV
symptom onset, and exposure to a new sexual partner
positively influenced BV acquisition. This same study re-
ported that women who co-enrolled with a BV-negative
partner reduced their risk of BV acquisition by 74 % [32].
Despite 60 years of research since the work of Leopold,
Gardner and Dukes in the 1950s, the causative or etiologic
agent(s) of BV has not been definitively established.
Therefore, it is difficult to state that BV constitutes a STI
or condition, although there is growing evidence support-
ing the hypothesis that BV is sexually transmitted [53]. As
an example, in the past decade, numerous studies have
reported the contribution of sexual activity to BV, and BV
has further emerged as a global issue of concern due to its
association with STIs [54]. Fig. 1 shows the timeline of the
main milestones of BV and its association with STIs. A
2009 systematic review and meta-analysis on sexual risk
factors associated with BV noted that the epidemiological
profile of BV is similar to common bacterial STIs, such as
chlamydia and gonorrhea. This would support the hypoth-
esis that BV is sexually transmitted and that the number
of sexual partners and condom use are risk and protective
factors for BV, respectively. For some researchers there is
a possibility that sexual activity may be a risk indicator for
BV transmission. For instance, Verstraelen stated that BV
constitutes a sexually enhanced disease, is not a classic
STI and that BV transmission increases with the fre-
quency of sexual intercourse [35]. Verstraelen also agreed
with Vallor [55] and Leppaluoto [56], both of whom
Fig. 1 Timeline and milestones related to bacterial vaginosis and associated sexually transmitted pathogens; 1879 to present. Note: BV,
bacterial vaginosis; H. vaginalis, Haemophilus vaginalis; STI, sexually transmitted infections; HIV, human immunodeficiency virus; C. trachomatis,
Chlamydia trachomatis
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course is associated with an imbalance of the vaginal
microflora in favor of BV-related microorganisms. In
contrast, Marrazzo suggests that there is evidence to
support a role for acquisition of BV, but this process
may vary among subsets of women [57]. Elevated cer-
vicovaginal levels of interleukin (IL)-1 beta, IL-6, and
IL-8, which are higher in pregnant adolescents with
BV, may increase one’s vulnerability to a STI [58].
Chlamydia and gonorrhea
Genital Chlamydia trachomatis (CT) is a common bac-
terial STI worldwide that is spread through oral, anal, or
vaginal sex in both women and men [59]. Based on US
National Health and Nutrition Examination Survey
(NHANES) data collected from 2007 to 2012, the preva-
lence of chlamydia has been estimated to be 1.7 %
among adults 14–39 years old [60]. Data from NHANES
also indicates that African-Americans (5.2 %), people
with two or more lifetime sexual partners (3.2 %), di-
vorced/widowed/separated participants (3.0 %), and par-
ticipants 20–24 years of age (2.9 %) have higher
infection rates. In the US, it is estimated that 2.8 million
cases of chlamydia are reported each year [61]. Accord-
ing to the Armed Forces Health Surveillance Center
(AFHSC), from 2000 to 2012, the human papillomavirus
(HPV, 304,021 cases), chlamydia (198,274 cases), and
gonorrhea (41,713 cases) were the three most frequently
diagnosed STIs among US military personnel on active
duty status [62].
One epidemiologic characteristic of a Chlamydia infec-
tion is that it is usually asymptomatic (~75 % in women,
~50 % in men) [63]. In women, common chlamydiasymptoms include abdominal pain, abnormal vaginal dis-
charge, intermenstrual bleeding, painful intercourse, burn-
ing while urinating, vaginal bleeding after intercourse, and
a yellow discharge with a strong odor [64]. In men, the
most common chlamydia symptom is urethritis, followed
by a burning sensation during urination, and itching of
the skin of the penis. Younger age is the main risk factor
associated with chlamydia among women, and 60–70 % of
chlamydia infections are reported among adolescents and
young adults <25 years of age [59]. Other risk factors asso-
ciated with infection are: 1) smoking; 2) substance use;
3) preceding HPV infection; 4) number of lifetime sex-
ual partners; 5) sex with new partners; 6) lack of con-
dom use, and 7) having a sex partner with a CT
infection, cervicitis, and/or prior history of chlamydia
or other STI [65, 66]. In women, chlamydia causes
cervicitis, urethritis, and endometritis. Untreated cervi-
citis can cause pelvic inflammatory disease (PID), ec-
topic pregnancy, infertility, and chronic pelvic pain. In
men, untreated chlamydia may cause tender or swollen
testicles and a decline in sperm mobility and concentra-
tion, which are both associated with infertility [66].
Neisseria gonorrhoeae (NG) is a bacterium that causes
gonorrhea, a curable and very contagious infection
transmitted through genital and anal sex and less fre-
quently through oral sex [67]. It constitutes the second
most common STI worldwide accounting for ~100 mil-
lion of the estimated ~500 million new cases of curable
STIs worldwide annually [68]. In the US, approximately
one million cases were reported at the disease’s peak in
1975, with decreasing incidence to 350,000 cases by the
year 2000. The principal factor in gonorrhea’s decline
was the widespread use of penicillin as a first line
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tional incidence of gonorrhea was 106.1 cases per
100,000 persons. Of the 333,004 cases reported that year,
93 % occurred in persons aged 15–44 years. Gonorrhea
is also commonly reported among active duty personnel
in the US Armed Forces, with stable incidence rates
since 2001 (~200 cases per 100,000 persons-years) [62].
In men, gonorrhea most commonly presents as acute
urethritis. Asymptomatic infection rates may be as high
as 75 %, in much the same manner as chlamydia infec-
tions are for women. In women, the bacteria initially
infect the endocervical canal causing gonococcal cervi-
citis; however, gonorrhea is asymptomatic in up to 70–
90 % of women, providing an important reservoir of
infection [70]. When symptomatic, common signs and
symptoms in women are vaginal discharge (green or
yellow color) with an unpleasant odor, together with
bleeding during sexual intercourse, painful urination,
or itching.
For both men and women, the strongest risk factor as-
sociated with a NG infection is young age (15–24 years)
[71]. Other risk factors/indicators include: 1) African-
American or Hispanic race/ethnicity; 2) illicit drug use; 3)
casual sex partners; 4) presence of other STI pathogens
(e.g., chlamydia); 5) history of STIs; 6) lack of barrier
contraception, and 7) inconsistent condom use [72, 73].
Biological, behavioral, and socio-cultural factors influence
the risk of gonorrhea transmission in adolescents and
young adult populations [74–76]. First, compared to olderTable 1 Summary of studies evaluating the association of bacterial
Reference Location Study design Population
Joesoef,
et al. [85]
Indonesia Cross-sectional Pregnant women
Keane, et al.
[86]








Mobasa, Kenya Cohort Sex workers
Wiesenfeld,
et al. [89]
Pennsylvania, US Cross-sectional Non-pregnant wom






Cohort Women visiting plan
university health clin
clinics, and STD unit
Allsworth,
et al. [91]





Alabama, US Cohort Non-pregnant wom
clinics for routine c
Gallo, et al.
[93]
Alabama, US Cohort Women attending p
STD clinicswomen, younger women have larger areas of cervical
ectropion and thus are biologically more susceptible to
infection. Second, sexually active younger populations
engage in more risky sexual behaviors (e.g., multiple
sexual partners) compared to the general population, in-
creasing the risk of infection. Finally, at the community
level, a gender imbalance represents a factor for transmis-
sion; in areas with more women than men, young women
are vulnerable to subtle coercion to engage in high-risk
sexual behaviors.
In the past decade, a new generation of non-culture
tests called nucleic acid amplification tests (NAATs),
which are both highly sensitive and specific, have revolu-
tionized diagnosis of gonorrhea and chlamydia infections
[77]. Two valuable characteristics of NAAT ‘testing’ are
the use of less invasive samples, including self-collected
specimens such as urine samples, and the possibility of
detecting both gonorrhea and chlamydia using the same
specimen [78].
Bacterial vaginosis and associations with HIV,
chlamydia, and gonorrhea
In 1995, Cohen reported a positive relationship between
BV and HIV in CSWs from Chiang Mai, Thailand [79].
Since then, this association has been reported in preg-
nant and postnatal women in Malawi, women in South
Africa, and CSWs in Kenyan, among others [80–82]. A
systematic review of 23 cohort studies estimated that BV
increases the risk of HIV by 60 % [83]. Althoughvaginosis with Chlamydia trachomatis and Neisseria gonorrhoeae
Findings
Women with BV had more than a 2-fold increase in
chlamydia and a 6-fold increase in gonorrhea
enitourinary Association between chlamydia and BV (odds ratio = 5.4)
amily planning BV is associated with sexual behavior risk factors similar
to those associated with Chlamydia
Absence of vaginal lactobacilli increased the risk of
gonorrhea (hazard ratio = 1.7)
en who
clinics
Women with BV were more likely to test positive





Baseline BV prevalence was associated with gonococcal
or chlamydial genital infection (OR = 2.8)
rimary care,
mily planning
Severity of BV (Nugent score >8) was associated with
the incident of a STI (C. trachomatis, N. gonorrhoeae,
Trichomonas vaginalis, or pelvic inflammatory disease)
en visiting
are
BV at the prior visit increased the risk of a subsequent C.
trachomatis (hazard ratio = 1.9) and N. gonorrhoeae
(hazard ratio = 1.8) infection
ublic BV increased the risk of gonorrhea/chlamydia (pairwise
odds ratio = 1.6) and gonorrhea/chlamydia also increased
the risk of BV (pairwise odds ratio = 2.4)
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onment (>4.5) may allow for the adherence and survival
of HIV, increasing the risk of HIV infection. Other stud-
ies also indicate that BV is a risk for both ulcerative (e.g.,
herpes simplex virus type 2 [HSV-2], syphilis [84] and
non-ulcerative STIs (e.g., gonorrhea, chlamydia).
The relevant epidemiological studies published on BV,
CT, NG and HIV are shown in Table 1. Joesoef in 1996 was
the first to report an association of BV with chlamydia
(two-fold increase) and gonorrhea (six-fold increase)
among pregnant women with BV in Indonesia and sug-
gested BV as a potential marker for these two common
bacterial STIs [85]. One year later, Keane conducted a case-
control study among 51 couples and observed a strong as-
sociation between chlamydia and BV (odds ratio = 5.4)
[86]. That same year, a large Swedish cross-sectional study
involving 1101 women found that high-risk sexual behav-
iors, such as a high number of lifetime sexual partners, a
history of anal sex, having multiple partners in the last
month, and a history of sexual abuse and rape were similar
among both BV and chlamydia patients [87]. In 1999,
Martin found that absence of vaginal lactobacilli increased
the risk of gonorrhea (hazard ratio = 1.7), but not chla-
mydia [88]. Wiesenfeld reported a strong relationship be-
tween BV and both CT and NG infections following
exposure to male partners with urethritis; this study was
conducted among 255 non-pregnant women 15–30 years
of age [89]. In this study, women with BV were 4.1 times
more likely to test positive for NG and 3.4 times more
likely to test positive for CT compared to women without
BV. Among 1179 African-American women who were
followed for 3 years with visits every 6 and 12 months
between 1999 and 2001, Ness et al., found that BV was as-
sociated with concurrent NG and CT infections at baseline
but not subsequently [90]. However, the authors conducted
a trial of NG/CT treatment during follow-up and this
might have affected their estimates. According to a second-
ary data analysis of 535 women at high-risk for STI,
Allsoworth observed that BV severity, as measured by a
high Nugent score (8–10), was associated with incident
STIs (NG, CT and Trichomonas vaginalis) and with severe
BV cases experiencing a 2-fold increased risk for STIs
compared to women with normal vaginal flora [91].
Findings from two cohort studies associating BV with
a CT or NG infection were published in 2010 and 2012
[92, 93]. Both studies were conducted among non-
pregnant women. According to Brotman’s study, which
was a secondary analysis of 3620 non-pregnant women
15–44 years of age enrolled in the Longitudinal Study of
Vaginal Flora in Birmingham, Alabama from 1999 to
2002, women with BV (measured as a Nugent score of
7–10) had a 1.8- and 1.9-fold increased risk for gonor-
rhea and chlamydia, respectively. The second cohort
study conducted by Gallo re-analyzed data from a largecondom intervention study among 1159 women who
attended public STI clinics between 1995 and 1998 in
Birmingham and Huntsville, Alabama, and used general-
ized estimating equations methods to account for multiple
individual visits (6 monthly follow-up visits). The authors
reported that women with an incident BV episode at a
prior visit were at a 1.6 times the risk of having chlamydia
or gonorrhea at a subsequent follow-up visit. In addition,
Gallo found a relationship between these two bacterial
STIs and BV; namely, chlamydia or gonorrhea increased
by 2.4 times the risk of having BV at a subsequent visit.
This represents the first report of a temporal relationship
working in both directions between BV and chlamydia/
gonorrhea. Recently, two studies have reported a signifi-
cant association between BV and these STIs among
women in Durban, South Africa and among female sex
workers in Uganda [58, 94].
Considered together, multiple studies report BV as a risk
factor or at least an important contributor in subsequent
gonorrhea or chlamydia infection. It is important to note
that the observation that BV increases the risk of chlamydia
or gonorrhea was mainly seen in high-risk women (e.g.,
CSWs, women attending STI clinics, and/or women at risk
for unplanned pregnancies). Additionally, the two recent
cohort publications are based on secondary data analyses
of data collected in the late 1990s to early 2000s, and their
findings must be interpreted with caution considering the
changes in the epidemiology of chlamydia in the US over
the past decade. We believe that additional research with
increased sample sizes and using modern epidemiological
and statistical methods in other young sexually active
women affected by these bacterial STIs are warranted. For
instance, women serving in the US Armed Forces can pro-
vide additional data-based evidence about the role of BV as
a risk factor or indicator for CT and NG infection. In
addition, molecular studies to determine risk factors and
adverse outcomes associated with the subtypes of BV in
different risk behaviors groups are also required. Data from
these studies may provide additional evidence as to the
epidemiology of this leading disorder among women of
reproductive age.
Prevention implications
Although a definitive causative agent for BV has not yet
been shown, there is evidence, albeit among higher risk
groups, that the presence of BV is positively associated with
both CT and NG occurrence. Existing findings to date sug-
gest that patients, clinicians and public health personnel
should be made aware of the positive association of BV
with CT and NG, and given the clustering of risk behaviors
behind both, should pay additional attention to education
on sexual hygiene measures (i.e., douching as a risk factor
for BV) and sexual risk behaviors for both BV and CT/NG
(i.e., younger age at sexual intercourse, higher number of
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most importantly the lack of barrier contraception). A clin-
ician diagnosis of BV can be a risk alert for eventual patient
acquisition of STIs and counseling is suggested, with
elevated concern for women presenting with repeat BV
infections. Despite the potential for prevention measures
associated with the identification of BV as a risk indicator
for common STIs, there is still the need for further
research among young women not in high risk sexual
behavior groups. Notwithstanding the need for additional
research information, data to date suggest a role for BV
diagnosis, treatment and prevention in STI prevention.
Conclusion
Since the discovery by Leopold in 1953 of the microorgan-
ism associated with non-specific vaginitis, now named
Gardnerella vaginalis, there has been increasing evi-
dence that the replacement of vaginal lactobacilli with
this microorganism is associated with BV and that it is
the most common cause of abnormal vaginal discharge
among women of reproductive age. Although the epi-
demiological profile of BV seems to be similar to chla-
mydia and gonorrhea, this cannot be interpreted as
evidence that BV is an STI. In the past decade, numer-
ous studies have reported an association between BV
and STI pathogens, such as HIV, HSV-2, CT, and NG.
The biological mechanisms underlying such an associ-
ation are still unknown; however, there is growing
evidence supporting the hypothesis that BV increases
the risk of acquiring STIs. Studies relating BV to chla-
mydia or gonorrhea were conducted mainly among non-
representative high-risk populations; thus, additional re-
search is required to determine whether these associations
are also present in other young sexually active populations
(e.g., among women in the US military). The effect of BV
on chlamydia or gonorrhea is an interesting area for future
research because there is evidence from two randomized
trials that screening and treating asymptomatic women
with BV reduces the risk of acquiring a CT or NG infec-
tion. Twice-weekly prophylactic use of intravaginal metro-
nidazole gel significantly reduced the incidence of CT
infections among women attending a STI clinic in Ala-
bama [95], and the incidence of CT and NG infections
was lower among US and African women who used intra-
vaginal metronidazole/miconzaole compared to the pla-
cebo group [96]. Therefore, to determine the role of BV as
a risk factor for CT/NG infections, it is essential to con-
duct large studies to provide solid epidemiological evi-
dence in favor of such associations.
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